Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2018 2
2019 2
2020 2
2021 6
2022 6
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study.
Grover NS, Hucks G, Riches ML, Ivanova A, Moore DT, Shea TC, Seegars MB, Armistead PM, Kasow KA, Beaven AW, Dittus C, Coghill JM, Jamieson KJ, Vincent BG, Wood WA, Cheng C, Morrison JK, West J, Cavallo T, Dotti G, Serody JS, Savoldo B. Grover NS, et al. Lancet Haematol. 2024 May;11(5):e358-e367. doi: 10.1016/S2352-3026(24)00064-4. Epub 2024 Mar 28. Lancet Haematol. 2024. PMID: 38555923 Clinical Trial.
T-cell lymphoma: the CAR-T revolution is coming.
Grover NS, Beaven AW. Grover NS, et al. Blood. 2024 Mar 28;143(13):1201-1202. doi: 10.1182/blood.2023023443. Blood. 2024. PMID: 38546636 No abstract available.
CARs for Hodgkin: engine fine-tuning is in order.
Grover NS, Ramos CA. Grover NS, et al. Blood Adv. 2024 Feb 13;8(3):799-801. doi: 10.1182/bloodadvances.2023012129. Blood Adv. 2024. PMID: 38349671 Free PMC article. No abstract available.
Building safety into CAR-T therapy.
Peters DT, Savoldo B, Grover NS. Peters DT, et al. Among authors: grover ns. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275457. doi: 10.1080/21645515.2023.2275457. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37968136 Free PMC article. Review.
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmán A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla N. Annunzio K, et al. Among authors: grover ns. Blood Adv. 2023 Nov 28;7(22):6839-6843. doi: 10.1182/bloodadvances.2023011288. Blood Adv. 2023. PMID: 37792806 Free PMC article. No abstract available.
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski AJ. Epperla N, et al. Among authors: grover ns. Blood Adv. 2023 Sep 12;7(17):5038-5046. doi: 10.1182/bloodadvances.2023010133. Blood Adv. 2023. PMID: 37315169 Free PMC article.
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmán A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski AJ. Epperla N, et al. Among authors: grover ns. J Hematol Oncol. 2023 May 8;16(1):49. doi: 10.1186/s13045-023-01448-y. J Hematol Oncol. 2023. PMID: 37158890 Free PMC article.
36 results